Clinical update: ATAGI statement on 2019 seasonal influenza vaccines
The Australian Technical Advisory Group on Immunisation has provided advice to support immunisation providers ahead of this year’s influenza season.
The Australian Technical Advisory Group on Immunisation (ATAGI) has provided advice to support immunisation providers ahead of this year's influenza season.
The ATAGI advice indicates:
- annual vaccination is the most important measure to prevent influenza and its complications
- annual influenza vaccination is recommended for all persons 6 months of age and over
- all Aboriginal and Torres Strait Islander people, including those aged 5 to 14 years, are now eligible to receive free annual influenza vaccination under the National Immunisation Program (NIP).
- for adults aged 65 years and over, two higher-immunogenicity trivalent influenza vaccine (TIV) formulations (one a 'high-dose' vaccine and another containing an adjuvant) are available
- in 2019, only Fluad® (TIV containing an adjuvant) is NIP funded
- the higher immunogenicity TIVs are preferentially recommended over quadrivalent influenza vaccines (QIVs) for adults aged ≥65 years
- there is no preference for use between either of these two TIVs
- QIVs continue to be clinically recommended for those under the age of 65 years
- all presentations of influenza vaccine brands registered and available in Australia for 2019 are latex free.
Please see ATAGI's clinical advice on 2019 seasonal influenza vaccines in full.